In “Impact of Mandibular Advancement Therapy on Endothelial Function in Severe Obstructive Sleep Apnea,” French researchers report on a randomized controlled trial of 150 patients with severe sleep apnea and no overt cardiovascular disease who received either a mandibular advancement device (MAD) or a sham oral appliance.
The researchers found MAD therapy significantly improved the apnea-hypopnea index (AHI) scores, micro-arousal index scores, and symptoms of snoring, fatigue, and sleepiness. However, MAD did not improve endothelial function, a key predictor of cardiovascular disease, or lower blood pressure.
Continuous positive airway pressure, or CPAP, is considered the “gold standard” of obstructive sleep apnea treatment. However, many patients find it uncomfortable, and MAD is the most commonly prescribed alternative.
“Endothelial dysfunction is one of the intermediate mechanisms that potentially contribute to the increased risk of cardiovascular disease in OSA,” said lead study author Frédéric Gagnadoux, MD, professor of pulmonology at the University Hospital of Angers in France. “Whether MAD therapy improves endothelial function in OSA patients had not been evaluated before in properly controlled and adequately powered trials.”
Patients in the current study had an AHI ≥ 30. They ranged in age from 18-70, and 86 percent were men. None had signs of cardiovascular disease. Although their AHI scores were indicative of severe sleep apnea, participants reported only mild daytime sleepiness. A strength of the study, which lasted two months, was that compliance with using MAD was high, as verified by researchers using a tiny embedded monitor.
“Our study demonstrates the effectiveness of MAD therapy in reducing sleep disordered breathing and improving related symptoms in patients with severe OSA who do not tolerate CPAP,” Dr. Gagnadoux said. “Despite being affected by severe OSA, our patients’ reactive hyperemia index (RHI), a validated marker of endothelial function, was within the normal range at baseline.”
Further studies, he added, are required to determine whether MAD therapy can improve endothelial function in OSA patients who exhibit endothelial dysfunction when they enroll, or have overt signs of cardiovascular disease or metabolic disorders.
The authors write that their negative findings on blood pressure outcomes should not be generalized to all OSA patients because study participants shared characteristics associated with lower blood pressure reductions in response to OSA therapy, including a low prevalence of hypertension and mild daytime sleepiness.
About the American Journal of Respiratory and Critical Care Medicine (AJRCCM):
The AJRCCM is a peer-reviewed journal published by the American Thoracic Society. The Journal takes pride in publishing the most innovative science and the highest quality reviews, practice guidelines and statements in pulmonary, critical care and sleep medicine. With an impact factor of 12.996, it is the highest ranked journal in pulmonology. Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.
About the American Thoracic Society:
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
The ATS will hold its 2017 International Conference, May 19-24, in Washington, DC, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.